There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (3)

Short Titles

Short Titles - Senate

Short Titles as Introduced

Preserving Access to Cost Effective Drugs Act

Official Titles

Official Titles - Senate

Official Titles as Introduced

A bill to amend title 35, United States Code, to provide that a patent owner may not assert sovereign immunity as a defense in certain actions before the United States Patent and Trademark Office, and for other purposes.

Actions Overview (1)

03/07/2018Introduced in Senate

All Actions (1)

03/07/2018Read twice and referred to the Committee on the Judiciary.
Action By: Senate

Cosponsors (4)

* = Original cosponsor
CosponsorDate Cosponsored
Sen. McCaskill, Claire [D-MO]* 03/07/2018
Sen. Perdue, David [R-GA]* 03/07/2018
Sen. Ernst, Joni [R-IA]* 03/07/2018
Sen. Toomey, Pat [R-PA]* 03/07/2018

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
Senate Judiciary03/07/2018 Referred to

No related bill information was received for S.2514.

Latest Summary (1)

There is one summary for S.2514. View summaries

Shown Here:
Introduced in Senate (03/07/2018)

Preserving Access to Cost Effective Drugs Act or the PACED Act

This bill prohibits patent owners from asserting tribal sovereign immunity as a defense in certain proceedings before the U.S. Patent and Trademark Office, including patent validity challenge proceedings before the Patent Trial and Appeal Board (PTAB). The prohibition also applies to court actions and proceedings before the International Trade Commission.

Sovereign immunity for foreign states shall apply in the PTAB as it applies in federal court.